retatrutide ly3437943 glp-1 gip glucagon receptor agonist triple phase 2 obesity LY3437943, a novel triple glucagon, GIP, and GLP-1 agonist for glycemic control and weight loss: From discovery to clinical proof of concept-camerecole Retatrutide 30 mg — ≥99%
Pay in 4 interest-free payments of $6.38 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23


























